In a Monday announcement, Chinese device maker Huawei has revealed that its Windows 10-based premium MateBook 2-in-1 tablet/laptop is now available for pre-order. The device, which was first unveiled by Huawei at the CES 2016 event, is scheduled to hit the US markets on July 11.
The Huawei MateBook 2-in-1 is available in four different configurations and corresponding price-points. All the models are equipped with a 12-inch touchscreen with 2,160 x 1,440 resolution; and are powered by Intel Core M-series processor.
Moreover, some of the other premium features of all the MateBook models include a Hello-capable fingerprint reader, stereo speakers, and USB Type-C.
The base model of the Huawei MateBook tablet/laptop is priced at $699 and it features Intel Core m3 processor, 4GB RAM, and 128GB SSD. A higher-spec model costs $849 and features Core m5 processor, 4GB RAM, 128GB SSD; while a $999-priced model comes with Core m5 processor, 8GB RAM, 256GB SSD. The top-end model is priced at $1,199 and it features Core m5 processor, 8GB RAM, 512GB SSD.
All the models come with an additional cost of $129 for MateBook Keyboard case; $89 for the portable MateDock; and $59 for the Huawei MatePen.
In a recently published blog post, "social media theorist" and Snapchat researcher Nathan Jurgenson has revealed that Snapchat is funding a new online magazine called 'Real Life.'
In announcing that Snapchat is bankrolling the new 'Real...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
During the course of Thursday proceedings in the ongoing legal scuffle between Google and Oracle...
Paying in cash is any day better than taking a loan from a loan shark. In good old days people used a wad of cash to pay everything starting from furniture to grocery, if they did not have enough, they would wait for something cheaper or for the...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
In an apparent attempt to enhance the visual experience for Google search users carrying out...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
In a recently published blog post, "social media...
With tech giant Google scheduled to launch the Play...
Monohm Inc.’s incredibly weird circular smartphone-cum-...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).
